Core Insights - Dianthus Therapeutics, Inc. is advancing its investigational monoclonal antibody, claseprubart, aimed at treating generalized Myasthenia Gravis (gMG) and will present Phase 2 trial results at the AANEM Annual Meeting [1][2] Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [5] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team from the biotech and pharmaceutical sectors [5] Product Details - Claseprubart (DNTH103) is designed to selectively inhibit the active form of the C1s protein, targeting the classical complement pathway, which is significant in autoimmune disease pathology [3] - The drug incorporates YTE half-life extension technology for convenient subcutaneous self-administration [3] - Claseprubart has the potential to be a best-in-class treatment across various autoimmune disorders with high unmet medical needs [3] Upcoming Events - The results from the Phase 2 MaGic trial will be presented on October 29, 2025, during the MGFA Scientific Session [2] - A virtual industry forum titled "Upstream Targeting: Rethinking MG Treatment Through Active C1s Inhibition" will also take place on the same day, featuring an expert panel [2]

Core Insights - Shattuck Labs, Inc. is participating in a panel discussion at the United European Gastroenterology Week (UEGW) Conference 2025, focusing on key takeaways from the event [1] - The panel will be moderated by analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., featuring KOL Marla Dubinsky, M.D. [1] Conference Details - The panel discussion titled "Wedbush UEGW Conference 2025 Rewind" will take place on October 8, 2025, from 10:00 am to 12:00 pm EST [2] - Shattuck's CEO, Taylor Schreiber, M.D., Ph.D., will represent the company during the session [2] Product Information - SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody aimed at achieving a complete and durable blockade of the DR3/TL1A pathway [2] - Preclinical studies of SL-325 show high affinity binding and superior activity compared to TL1A antibodies, indicating potential for higher efficacy and lower immunogenicity [2] - SL-325 is currently undergoing a Phase 1 clinical trial [2] Company Overview - Shattuck Labs, Inc. specializes in developing treatments for inflammatory and immune-mediated diseases, with a focus on inflammatory bowel disease (IBD) [3] - The company leverages its expertise in protein engineering to develop novel TNF receptor therapeutics, with SL-325 being its lead program [3] - Shattuck Labs operates offices in Austin, Texas, and Durham, North Carolina [3]

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics. Why Is MoonLake being Investigated?MoonLake is a clinical stage biotechnology company focusing on therapies to address inflammato ...

Market Overview - U.S. stock futures showed mixed performance following record advances on Wednesday, with Dow Jones futures down 0.04%, S&P 500 futures up 0.17%, Nasdaq 100 futures up 0.36%, and Russell 2000 futures up 0.41% [3] - The Dow Jones index closed 43 points higher at 46,441.10, S&P 500 rose 0.34% to 6,711.20, Nasdaq Composite advanced 0.42% to 22,755.16, and Russell 2000 gained 0.24% to 2,442.35 [7][8] Economic Impact of Government Shutdown - The Trump administration warned that a government shutdown could reduce weekly GDP by $15 billion and increase unemployment by 43,000 if it lasts a month [1] - The Senate rejected funding bills, with the next voting opportunity scheduled for Friday [2] - Wall Street is currently overlooking the potential economic consequences of the shutdown, which could significantly impact businesses reliant on federal operations [5] Employment Data - The ADP monthly employment report indicated a surprising drop in private payrolls, with a loss of 32,000 jobs, missing forecasts of a gain of over 50,000 [6] Analyst Insights - Brian Rehling from Wells Fargo suggests that the government shutdown will likely have a negligible long-term impact on the economy and markets, although it may cause short-term volatility [10] - Rehling notes that the biggest market impact would be the delay of key economic reports, which are crucial for the Federal Reserve's data-dependent monetary policy [11] - Rehling anticipates that any market pullback could present an opportunity for investors to reposition their portfolios [12] Sector Performance - Gains were observed in Health Care and Utilities sectors, while Materials and Financials experienced losses [4] - Wells Fargo rates Financials, Information Technology, and Industrials as favorable sectors for investment [17] Upcoming Economic Data - Key economic data releases, including initial jobless claims and the September jobs report, will be delayed due to the government shutdown [15][16] Stocks in Focus - AngioDynamics, Inc. saw a premarket jump of 6.14% ahead of its earnings report [21] - Gulf Island Fabrication Inc. rose 9.25% after securing a $35 million fabrication contract [21] - Concorde International Group Ltd. surged 55.25% following the approval of a 2025 Equity Incentive Plan [21]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Galapagos on Wednesday announced that a “limited number” of potential buyers for its cell therapy business have come forward, and the company plans to announce the fate of the unit in coming weeks. The interested parties are consortia, mainly made up of financial investors, Galapagos said. The company’s board and executives are working with the p ...

Core Insights - Eleven Chinese healthcare and biotechnology companies have filed for initial public offerings (IPOs) on the Hong Kong stock exchange, capitalizing on a booming investment environment in the sector [1][2] - Notable companies among the IPO applicants include We Doctor Holdings, Sichuan Biokin Pharmaceutical, and Betta Pharmaceuticals, indicating strong interest from established firms [1][2] - The Hang Seng Biotech index has experienced a significant increase of 109% this year, recovering from a previous decline of 70% since mid-2021 [5] Company Summaries - We Doctor Holdings is an online healthcare services firm seeking to leverage the current market conditions for its IPO [1] - Sichuan Biokin Pharmaceutical is recognized for a substantial US$8.4 billion licensing deal with Bristol Myers Squibb, highlighting its strategic partnerships [1] - Betta Pharmaceuticals is a profitable cancer-drug developer, showcasing the potential for growth in the oncology sector [1] Industry Trends - A total of at least 23 IPO applications were recorded in September, with a focus on drug and medical-device developers, reflecting a robust interest in the healthcare sector [5] - The surge in IPO applications is attributed to a combination of fund flow and a favorable out-licensing sentiment, with Chinese firms engaging in 95 out-licensing deals worth US$89 billion, representing 33% of the global total [6] - The healthcare rally in Hong Kong and China is indicative of a broader trend in the biotechnology and pharmaceutical industries, driven by increased investment and strategic collaborations [6]

Core Insights - Defence Therapeutics Inc. has appointed Dr. Mark Lambermon as Head of Quality and Operations, bringing over 20 years of experience in pharmaceutical R&D and biotech innovation [1][2] - Dr. Lambermon's expertise will be crucial for the company's regulatory readiness and operational excellence as it advances its drug delivery technologies [3] - The company has granted Dr. Lambermon 100,000 incentive stock options, exercisable at $0.80 per share for three years [4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells [5]

Core Insights - BeOne Medicines Ltd. (NASDAQ:ONC) is highlighted as a top biotech stock to consider for investment, with Barclays initiating coverage and rating it Overweight, setting a price target of $385 for the shares [1] Group 1: Anticipated Data Readouts - The first key catalyst for BeOne is the upcoming data on its BTK inhibitor for first-line mantle cell lymphoma, expected in the latter half of 2025 [2] - Additionally, data for BeOne's PD1 inhibitor combined with anti-HER2 for first-line gastroesophageal cancer is anticipated in the fourth quarter of 2025 [2] Group 2: Significance of Pivotal Data - A crucial driver for BeOne's growth is the topline pivotal data for zanidatamab, with or without tislelizumab, in first-line gastroesophageal adenocarcinoma [3] - BeOne Medicines Ltd. specializes in oncology treatments, focusing on blood cancers and solid tumors [3]

Core Insights - Moderna, Inc. is recognized as one of the top biotech stocks to invest in, with Brookline Capital Markets maintaining a Buy rating and a price target of $198 as of September 23 [1][3]. Company Overview - Moderna, Inc. is a biotechnology company focused on the discovery, development, and commercialization of mRNA-based medicines and vaccines, gaining significant recognition for its COVID-19 vaccine, one of the first mRNA vaccines delivered globally [4]. Vaccine Performance - The mNEXSPIKE/mRNA-1283 vaccine has shown a remarkable increase in neutralizing antibodies against the LP.8.1 variant, averaging over sixteen times compared to the initial COVID-19 vaccination results, which Brookline described as "remarkably strong" [2]. Sales Projections - Moderna's COVID-19 vaccine sales are projected to reach 10.9 million units in the U.S. this year, a decrease from the expected 14.6 million in 2024. Global sales are anticipated to be $2.1 billion in 2025 and could rise to $15.6 billion by 2030 [3].

Core Insights - Longeveron Inc. has elected Dr. George Paletta, Jr. to its Board of Directors, bringing extensive experience in medicine and entrepreneurship to the company [2][3] - The company is focused on developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, with a promising pipeline of stem cell therapies [2][6] Company Overview - Longeveron is a clinical stage biotechnology company that develops regenerative medicines to address unmet medical needs, with its lead product being laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy [6] - The company is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty [6] - Laromestrocel has received five important FDA designations, including Orphan Drug designation and Fast Track designation for the HLHS program [6] Leadership and Expertise - Dr. Paletta is a recognized orthopedic surgeon and has significant experience in developing ambulatory surgical centers, having participated in the sale of two ASCs valued at nearly $1 billion [2][3] - He holds multiple patents in orthopedic and cardiovascular fields and has been involved in various start-up ventures, providing advisory roles [3][4] - Dr. Paletta's educational background includes a Doctor of Medicine from Johns Hopkins University and an MBA from Washington University in St. Louis [4]